SHH and lung carcinoma: We proposed that lung cancer patients with the expression profile of ZNF322Ahigh/Shhhigh/CD31high may be selected for further treatment with Shh neutralizing antibodies, although targeting Shh via antibodies has not reached human trials 40,41.